Research data
Research data is crucial in cancer medicine to improve cancer treatment and research. Careful data collection and management at our Cancer Center make it possible to gain valuable insights and develop new therapies. The Cancer Registry of Lower Saxony (KKN) plays a central role in this by collecting extensive information on cancer diagnosis, treatment and progression. Initiatives within the framework of national research networks, such as PM4Onco and the Clinical Communication Platform (CCP), support networking and the secure exchange of data between different research institutions. Data Protection is of the utmost importance in order to protect sensitive patient data. Comprehensive tumor documentation and the use of modern technologies ensure that research data is processed efficiently and in compliance with data protection regulations.
Clinical, i.e. patient-related data is a very central basis for cancer research. This data is required in order to be able to use diagnoses, therapies and disease progression, sometimes in combination with data on quality of life, molecular information, etc., for very different questions. Projects can focus on linking forms of cancer with characteristic cell functions, therapy response and side effects, as well as evaluating innovative surgical procedures and the effects of treatments on the quality of life of those affected.
In healthcare research, the transition to quality assurance of medical treatment is difficult to define. The specific questions are often not even known at the start of data collection. There is therefore a legal basis for the collection and use of this disease data, which enables epidemiological and clinical cancer registries.
For the CCC Hannover, the legally prescribed recording of all cancer patients is carried out through tumor documentation. The OnkoStar database system and the Oncological Basic Data Set with its modules, which is compiled by ADT and GEKID on a nationwide basis, serve as the technical basis. Experienced documenters guarantee a very high level of quality, completeness and completeness of this data. This data is reported to the Lower Saxony State Cancer Registry.
The Clinical State Cancer Registry of Lower Saxony (KKN) has the task of obtaining valid information on the occurrence, treatment and progression of tumor diseases for the whole of Lower Saxony. On this basis, the care of cancer patients in the state is to be improved. Regular analyses and evaluations of the data should reveal potential for improved therapeutic measures. The lively exchange of information between all those involved is in the interests of patients. The experts at the CCC Lower Saxony are available to advise the KKN, particularly in the evaluation of quality assurance data. The KKN is involved in the research activities as a partner institution of the CCC Lower Saxony.
The Epidemiological State Cancer Registry of Lower Saxony (EKN) records reports of newly diagnosed tumor diseases throughout Lower Saxony and regularly evaluates them according to epidemiological criteria.
The KKN and the EKN operate a joint data collection point with an electronic reporting portal. Options for consenting to and rejecting the storage and use of data are based on the relevant legal provisions of the state of Lower Saxony. Further information on this can be found on the KKN Lower Saxony website.
PM4Onco - "Personalized Medicine for Oncology" is one of the largest projects of the nationwide Medical Informatics Initiative (MII). In many tumor diseases, therapies can now be targeted specifically to the genetic characteristics of the tumor and its growth inhibited. This is made possible by molecular genetic tests that determine the exact changes in the genetic material responsible for the cancer. Experts see these diagnostic methods and the targeted intervention in the disease as the cancer medicine of tomorrow. In order to support the experts involved, it is necessary to bring together the data obtained in the Clinical Department and research across all locations and make it available to all those involved. This is the goal of PM4Onco.
The Clinical Communication Platform (CCP) is a project of the German Consortium for Translational Cancer Research (DKTK). As an IT infrastructure, the CCP networks all associated sites of the consortium and enables researchers to carry out feasibility assessments for clinical trials, among other things, using the shared data pool of data from tumor documentation and biomaterial databases. This is an important prerequisite for planning oncological studies.
Two search functions are available in the CCP: Firstly, the centralized search, which allows researchers to search the dataset of a central database to identify sites where data is available that could be relevant to a research project. The second is the decentralized search, which queries location-specific data. In the future, a "virtual cohort" will provide an overview of the data in the network, in which the CCP data will be analyzed (e.g. cohort growth, patient demographics, diagnosis-specific overview). This will enable researchers to better assess the extent to which their own project could benefit from the CCP, or to obtain ideas for future studies.
The CCP gives researchers access to biosamples and patient data across all sites while maintaining the highest data protection standards. As a cooperating Facilities or Institutions, all MHH researchers can gain access to the CCP. After an internal check, they receive a DKTK account with which they can use the searches. Contact: ccc-it@mh-hannover.de
Further contacts and contact persons
Tumor documentation Data Protection MHH Medical Data Integration Centre (MeDIC)Contact the CCC-IT
Peter Helmig, IT Coordination |